Patents Assigned to Shenogen Pharma Group Ltd.
  • NANO-MICELLE PREPARATION OF ICARITIN AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
    Publication number: 20220249370
    Abstract: A nano-micelle preparation of icaritin. The preparation comprises icaritin and polymer auxiliary materials. Further provided is a preparation method for the nano-micelle preparation, and the prepared nano-micelle preparation of icaritin has the advantage of high bioavailability.
    Type: Application
    Filed: July 26, 2020
    Publication date: August 11, 2022
    Applicant: BEIJING SHENOGEN PHARMA GROUP LTD.
    Inventors: Cheng TANG, Xiaoming CHEN, Hua YAO, Ranran ZHANG, Kun MENG
  • Antibodies and methods for treating estrogen receptor-associated diseases
    Patent number: 10233249
    Abstract: Provided herein in certain embodiments are antibodies, antibody fragments, pharmaceutical compositions, methods for modulating the functions of estrogen receptor alpha 36, and methods for preventing and/or treating diseases mediated by estrogen receptor alpha 36.
    Type: Grant
    Filed: March 19, 2014
    Date of Patent: March 19, 2019
    Assignee: BEIJING SHENOGEN PHARMA GROUP LTD.
    Inventors: Xueming Qian, Kun Meng, Feng Chen, Xiao Shang, Jing Wang, Lu Li, Congya Zhou
  • Use of icaritin for the preparation of composition for treating cancer
    Patent number: 9301942
    Abstract: The present invention provides the use of Icaritin for the preparation of a composition for treating cancer, wherein the composition is orally administered to a patient at least one cycle, each cycle comprising a continuous 28-day dosing schedule, in which Icaritin is administered at least once daily, at a dosage of 400-1800 mg daily. The patients treated with Icaritin according to the present method receive better treatment, with reduced adverse effects.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: April 5, 2016
    Assignee: BEIJING SHENOGEN PHARMA GROUP LTD.
    Inventors: Kun Meng, Hongxia Ding, Shu Li, Ya Tuo, Yueqiu Shen
  • ANTIBODIES AND METHODS FOR TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES
    Publication number: 20160046721
    Abstract: Provided herein in certain embodiments are antibodies, antibody fragments, pharmaceutical compositions, methods for modulating the functions of estrogen receptor alpha 36, and methods for preventing and/or treating diseases mediated by estrogen receptor alpha 36.
    Type: Application
    Filed: March 19, 2014
    Publication date: February 18, 2016
    Applicant: BEIJING SHENOGEN PHARMA GROUP LTD.
    Inventors: Xueming QIAN, Kun MENG, Feng CHEN, Xiao SHANG, Jing WANG, Lu LI, Congya ZHOU
  • Benzopyrone estrogen receptor regulator
    Patent number: 9090583
    Abstract: The present invention provides a kind of benzopyrone compounds having a structure of formula (I) and the pharmaceutically acceptable salts or prodrugs thereof, and the pharmaceutical compositions containing such compounds, which can be used to regulate the novel estrogen receptor ER-a36, and prevent and/or treat the related diseases mediated by the ER-a36 receptor, such as cancers, etc.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: July 28, 2015
    Assignee: BEIJING SHENOGEN PHARMA GROUP LTD.
    Inventors: Hongxia Ding, Kun Meng, Jin Li
  • SYNTHESIS OF POLYHYDROXY CHROMENONE COMPOUNDS AND THEIR ANTI-TUMOR EFFECTS
    Publication number: 20150011618
    Abstract: The present invention is directed to chromenone compounds of formula (I), pharmaceutically acceptable salts, prodrugs thereof, and the composition comprising the compounds or the like. They can be used to modulating the function of estrogen receptor ER-?36 preventing and/or treating the estrogen related diseases, such as breast cancer, leukemia, liver cancer and etc.
    Type: Application
    Filed: December 31, 2012
    Publication date: January 8, 2015
    Applicant: BEIJING SHENOGEN PHARMA GROUP LTD.
    Inventors: Hongxia Ding, Jin Li, Kun Meng
  • USE OF ICARITIN FOR THE PREPARATION OF COMPOSITION FOR TREATING CANCER
    Publication number: 20140357876
    Abstract: The present invention provides the use of Icaritin for the preparation of a composition for treating cancer, wherein the composition is orally administered to a patient at least one cycle, each cycle comprising a continuous 28-day dosing schedule, in which Icaritin is administered at least once daily, at a dosage of 400-1800 mg daily. The patients treated with Icaritin according to the present method receive better treatment, with reduced adverse effects.
    Type: Application
    Filed: May 30, 2014
    Publication date: December 4, 2014
    Applicant: BEIJING SHENOGEN PHARMA GROUP LTD.
    Inventors: Kun MENG, Hongxia DING, Shu LI, Ya TUO, Yueqiu SHEN
  • BENZOPYRONE ESTROGEN RECEPTOR REGULATOR
    Publication number: 20130303544
    Abstract: The present invention provides a kind of benzopyrone compounds having a structure of formula (I) and the pharmaceutically acceptable salts or prodrugs thereof, and the pharmaceutical compositions containing such compounds, which can be used to regulate the novel estrogen receptor ER-a36, and prevent and/or treat the related diseases mediated by the ER-a36 receptor, such as cancers, etc.
    Type: Application
    Filed: December 21, 2011
    Publication date: November 14, 2013
    Applicant: BEIJING SHENOGEN PHARMA GROUP LTD.
    Inventors: Hongxia Ding, Kun Meng, Jin Li
  • Compounds and methods for treating estrogen receptor-related diseases
    Patent number: 8252835
    Abstract: Provided herein in certain embodiments are compounds, pharmaceutical compositions and methods for modulating the functions of estrogen receptor alpha 36, for preventing and/or treating diseases related to estrogen receptor alpha 36, for preventing and/or treating respiratory diseases such as asthma, for inducing cell death and/or inhibiting cell proliferation and for preventing and/or treating diseases involving abnormal cell proliferation such as cancers.
    Type: Grant
    Filed: October 23, 2007
    Date of Patent: August 28, 2012
    Assignee: Shenogen Pharma Group Ltd.
    Inventors: Jin Li, Kun Meng
  • Antibodies and methods for treating estrogen receptor-associated diseases
    Publication number: 20110311517
    Abstract: Provided herein in certain embodiments are antibodies, antibody fragments, pharmaceutical compositions, methods for modulating the functions of estrogen receptor alpha 36, and methods for preventing and/or treating diseases mediated by estrogen receptor alpha 36.
    Type: Application
    Filed: February 10, 2010
    Publication date: December 22, 2011
    Applicant: SHENOGEN PHARMA GROUP, LTD.
    Inventors: Jin Li, Kun Meng
  • COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES
    Publication number: 20080146658
    Abstract: Provided herein in certain embodiments are compounds, pharmaceutical compositions and methods for modulating the functions of estrogen receptor alpha 36, for preventing and/or treating diseases related to estrogen receptor alpha 36, for preventing and/or treating respiratory diseases such as asthma, for inducing cell death and/or inhibiting cell proliferation and for preventing and/or treating diseases involving abnormal cell proliferation such as cancers.
    Type: Application
    Filed: October 23, 2007
    Publication date: June 19, 2008
    Applicant: SHENOGEN PHARMA GROUP LTD.
    Inventors: Jin Li, Kun Meng